Leerink sees UnitedHealth stock facing largest RADV audit exposure By Investing.com

CMS is substantially expanding 2020 RADV audits to 470 unique Medicare Advantage contracts (vs. 58 in 2018), with processing to begin in April 2025 and each contract subject to review of 35–200 members' records. UnitedHealth has the largest absolute exposure with 60 contracts covering ~92% of its >6M 2020 MA membership; Humana has 42 contracts representing ~99% of membership within named contracts. CMS expects a third party to handle an estimated 20 million–200 million PDF pages for up to 100,000 HCC appeals and has not decided whether extrapolation will occur at the contract, company, or sample level. Leerink’s analysis shows largely stable 2024 risk-score trends, with UnitedHealth and Elevance highest on weighted average risk scores and CVS lowest among the covered firms.

Analysis

The expanded RADV audit scope creates a binary, asymmetric risk for Medicare Advantage–heavy insurers: the market is pricing in a slow, administrative process, but extrapolation at a portfolio or company level would compress near-term earnings and capital returns materially. For a large MA franchise, a modest 1–2% downward adjustment in risk scores (or equivalent clawback) can translate into mid-to-high hundreds of millions of dollars of payment reversals — enough to force incremental reserve builds or pause share buybacks over 6–18 months. Smaller or recently public plans have much thinner capital buffers and concentrated contract footprints, so the same absolute repayment can represent low-double-digit percent shocks to market cap and could trigger covenant strain or accelerated M&A interest.

Key catalysts to watch are procedural: CMS’s stated decision on whether extrapolation will be applied, the vendor’s processing cadence when audits begin, and the timeline for the first set of finalized audit determinations. Each milestone has the potential to reprice risk — particularly the extrapolation determination (binary, likely to move stocks >10% for the most exposed names). Legal outcomes and appeals will stretch the effective timeline into multiple years, so trading should focus on discrete catalysts within the next 3–12 months while maintaining a view to longer-term resolution risk.

Second-order winners include diversified health platforms and PBMs with lower MA concentration which could capture reallocated enrollment if smaller MA players de-risk or exit; conversely, firms that rely on MA margin stability (tech-enabled MA entrants, certain care-management providers) are vulnerable to revenue and contract renegotiation. The consensus is underweighting the operational shock to capital allocation — the first audit outcomes may force materially different capital return and M&A behavior from incumbents, creating tactical dispersion across the sector.

Key Decisions for Investors

• Pair trade (3–9 months): Short UNH (or buy UNH 3–6 month 5–7% OTM put spread) vs Long CVS (buy CVS 3–6 month 2–4% OTM call or simply overweight) — rationale: express relative safety of lower MA-risk franchise. Target asymmetric payoff of ~2.5:1 if CMS applies extrapolation; max loss = option premium or stock move against position.
• Directional short (6–12 months, high conviction on capital stress): Buy long-dated (6–12 month) OTM puts on ALHC and CLOV (or put spreads to limit premium) — small notional sizes given idiosyncratic liquidity risk; expect skewed payoff if audits trigger material membership loss or regulatory capital action.
• Capital preservation trade (3–6 months): For HUM, purchase a collar (sell near-term calls to finance 3–6 month 3–5% OTM puts) to hedge downside while retaining limited upside; works if you want to maintain exposure but cap near-term tail risk. Aim to limit downside to ~10–12% while capping upside to similar magnitude.
• Event contingent (watchlist/alert): Establish size-limited option positions ahead of CMS extrapolation decision — buy cheap digital/one-touch structures or deep OTM puts on names with highest relative exposure to create 5–10x payoff if extrapolation is applied at company level. Exit if CMS rules out extrapolation.
• Opportunistic long (12–24 months): Accumulate larger-cap insurers with diversified revenue (lower MA share) on pullbacks of 8–15% as potential beneficiaries of enrollment flow and consolidation; use size discipline — target 12–18% IRR-style upside if smaller players are forced to divest or exit contracts.